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Background/aim: Programmed death pathway leads to T cell anergy. Wide range of malignancies take advantage of this pathway by
programmed death-ligand 1 (PD-L1) expression either on neoplastic cells or on the nonneoplastic cells of tumour microenvironment.
New therapeutic approaches have been directed against this pathway. We studied PD-L1 expression on both neoplastic Hodgkin and
Reed–Sternberg (HRS) cells and cells of tumour microenvironment in classic Hodgkin lymphoma (CHL) patients and compared it with
Ebstein–Barr virus (EBV) positivity, clinical data, and survival rates.
Materials and methods: Lymph node excision materials of 56 CHL patients diagnosed between 2007 and 2017 were included in this
retrospective study. PD-L1 expression of HRS cells and tumour microenvironment cells were evaluated by immunohistochemical assay.
Staining intensity and rate of the PD-L1 expressions were estimated. EBV was examined by immunohistochemistry for latent membrane
protein 1 (LMP1) antibody. Clinical data of 39 patients and survival data of 34 patients were compared with PD-L1 expressions on
tumour cells.
Results: PD-L1 expression was present in HRS cells in 89.2% of the cases. There was more than 20% of PD-L1 expression in cells of
tumour microenvironment in all the cases. PD-L1 positivity did not show statistically significant difference according to EBV expression,
clinical parameters, and prognosis.
Conclusion: Previous studies showed inconsistent rates for PD-L1 prevalence (20%–95.7%) in CHL patients due to differences in
the study methods. Although high prevalence of PD-L1 positivity was found in majority of them, there was no statistically significant
difference between PD-L1 positivity on HRS cells and EBV expression, clinical parameters, and prognosis. This high prevalence in
patients with various clinical properties makes PD-L1 a potential target for new emerging immunotherapies for CHL.
Key words: Hodgkin lymphoma, programmed death-ligand 1, Ebstein–Barr virus, prognosis

1. Introduction
Antigen presentation to T-Helper (Th) cells is achieved by
the interaction between major histocompatibility complex
(MHC) protein on the surface of antigen presenting cells
(APCs) and T-cell receptor (TCR) on the surface of Th cells.
It is controlled by the programmed death (PD) pathway,
which consists of the programmed death-ligand 1 (PD-L1)
protein on the surface of APC, and its receptor programmed
cell death protein 1 (PD1) on the surface of T cells. PD-L1
activates PD1, which inhibits TCR expression on the T cells
and stops inflammation [1].
Malignancies can also escape from cellular immunity due
to PD-L1 expressed either by the neoplastic cells themselves
or by the reactive cells in tumour microenvironment. For
this reason, there are many attempts for a monoclonal
antibody therapy against the PD pathway. Such molecules
are currently being used against other malignancies [1-3].

Classic Hodgkin lymphoma (CHL) derives from the
germinal centre B cells that have lost their ability to synthesize
immunoglobulins. Neoplastic Hodgkin and Reed–Sternberg
(HRS) cells constitute about 1% of the total tumour area; the
rest is reactive cells consisting of lymphocytes, macrophages,
eosinophils, neutrophils, and fibroblasts [4]. Although it
depends on histological subtype and geographical region,
nearly half of the cases are Ebstein–Barr virus (EBV)-positive.
Studies show that latent membrane protein 1 (LMP1), a viral
protein, has a role in the pathogenesis [5-7]. Recently, two
anti-PD1 molecules, nivolumab and pembrolizumab, are
approved by the Food and Drug Administration (FDA)
for the CHL patients who have relapsed disease after bone
marrow transplantation [8,9].
There are several articles in the literature that study
expression rates alone or with clinical correlation.
However, there is variability in both expression rates and
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clinical correlation. The aim of this study is to determine
the PD-L1 and EBV LMP1 expressions in classic Hodgkin
lymphoma and its correlation with clinicopathological
parameters and prognosis.
2. Material and method
2.1. Patients
Lymph node excisions of 56 patients diagnosed with CHL
between 2007 and 2017 in our pathology department were
included in this retrospective study. Clinical data (age, sex,
stage on diagnosis, B symptoms, splenic or bone marrow
involvement, extranodal involvement) of 39 patients were
found and prognostic data (overall monitored time, overall
disease-free survival time, relapse, death from disease)
of 34 patients could be obtained from hospital records
(Table 1). They had got either standard brentuximab
vedotin, doxorubicin, vinblastine, dacarbazine (ABVD)
or bleomycin, etoposide, doxorubicin hydrochloride
(adriamycin), cyclophosphamide, vincristine (oncovin),
procarbazine and prednisone (BEACOPP) protocols with
or without radiotherapy according to current protocols at
the time of diagnosis.
2.2. Immunhistochemistry
Three-micrometre thick slices of paraffin-embedded
blocks on positive charged slides were prepared.
Immunohistochemistry
staining
was
performed
on Leica Bond III autostainer using PD-L1 (clone:
E1L3N, Cell Signaling Technologies, USA) and EBV
LMP1 (clone: MRQ-47, Cell Marque, USA) with the
3,3′-Diaminobenzidine (DAB) peroxidase method.
Membranous staining for PD-L1 was evaluated via
conventional light microscope in HRS cells and the
cells of tumour microenvironment. In previous studies,
similar criteria were used for staining characteristics and
intensity, but different cut-off values were used to evaluate
tumour cells and microenvironment [10-15]. We chose
E1L3N clone, which has been validated with standard

clones, for selective HRS staining [14]. We first used %5
PD-L1 staining as cut-off value for HRS cells and then
evaluated the staining quality in three categories. Tumours
with less than 5% of HRS cells stained with PD-L1 were
categorized as negative (0), and then tumours which had
PD-L1 staining in at least 5% of HRS cells were categorized
qualitatively for staining intensity as weak (+1), moderate
(+2), and strong (+3). Finally, patients with moderate
(+2), and strong (+3) staining in at least 5% of HRS cells
were considered “positive for PD-L1”, and others were
considered “negative for PD-L1” (Figures 1–3). Tumours
which had 20% or more PD-L1 staining in nonneoplastic
cells were considered “positive tumour microenvironment”
(Figure 4). Placental tissue was used for external positive
control [10]. Membranous and cytoplasmic staining for
EBV LMP1 in HRS cells was considered positive (Figure 5).
2.3. Ethical approval
All procedures performed in studies involving human
participants were in accordance with the ethical standards
of the institutional and/or national research committee
and with the 1964 Helsinki Declaration and its later
amendments or comparable ethical standards. The
study was approved by the Bioethics Committee of Şişli
Hamidiye Etfal Health Practice and Research Centre (No.
2579/2019).
2.4. Statistical analysis
Statistical analysis was performed with SPSS programme
version 25.0 (IBM SPSS Statistics, USA). Descriptive
statistics were number and percentage for categorical
variables; median, minimum, and maximum for numerical
variables. Comparisons of numerical variables in two
independent groups were performed with the Mann–
Whitney U test since normal distribution condition was
not provided. The ratio of categorical variables between
the groups was tested by chi-squared analysis. Monte Carlo
simulation was applied when the conditions were not met.
Statistical significance level was accepted as p < 0.05.

Figure 1. Weak (+1) membranous staining for PD-L1
in HRS cells (arrows) (×400).

Figure 2. Moderate (+2) membranous staining for
PD-L1 in HRS cells (arrows) (×400).
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Figure 3. Strong (+3) membranous staining for PDL1 in HRS cells (arrows) (×400).

Figure 4. PD-L1 positivity in
microenvironment (arrows) (×200).

the

tumour

Figure 5. Membranous and cytoplasmic staining for
EBV LMP1 in HRS cells (arrows) (×400).

3. Results
3.1. Clinical and prognostic parameters
Thirty-nine patients were male (69.6%), 17 patients were
(30.4%) female. Median age of the patients was 26 years;
age interval was between 3 and 85 years. Cases were
categorized for the histological subtypes as 25 (44.6%)
nodular sclerosing subtype, 29 (51.8%) mixed cellularity
subtype, 1 (1.8%) lymphocyte-rich subtype, and 1 (1.8%)
lymphocyte-depleted subtype.
Clinical findings at the time of diagnosis could be
obtained for 39 patients. Four of them (10.3%) were
stage-1, 19 (48.7%) were stage-2, 9 (23.1%) were stage-3,
and 7 (17.9%) were stage-4. Seven (17.9%) patients had
splenic involvement, 4 (10.3%) patients had extranodal
involvement, and 3 (7.3%) had bone marrow involvement.
Twenty (51.3%) patients had B symptoms.Clinical followup of 34 patients showed that 27 (81.8%) were on remission,
1 (2.9%) was continuing therapy, 4 (12.1%) relapsed during
follow-up, and 2 (5.9%) died from the disease (Table 1).
3.2. PD-L1 expression in CHL patients
Fifty (89.2%) of the cases had HRS cells “positive for
PD-L1”. For nodular sclerosing subtype of CHL cases,

24 (96%) were positive for PD-L1. For mixed cellularity
subtype CHL cases, 25 (86.2%) were positive for PDL1. One case with lymphocyte-rich subtype of CHL was
positive for PD-L1 and one case with lymphocyte-depleted
subtype of CHL was negative for PD-L1. All cases had
tumour microenvironment positive for PD-L1. There was
no statistically significant difference among histological
subtypes for PD-L1 positivity (p = 0.102) (Table 2).
3.3. EBV and PD-L1
EBV was positive in 29 patients (51.7%) (Table 1). Eight
patients (32%) with nodular sclerosing subtype, 17 patients
(68%) with mixed cellularity subtype, and one patient
with lymphocyte-rich subtype were positive for EBV. One
patient with lymphocyte-depleted subtype was negative
for EBV. EBV positivity was statistically significantly
higher on mixed cellularity subtype CHL compared to the
remaining subtypes (p = 0.01). Mixed cellularity subtype
CHL had significantly high EBV expression (Table 2).
Twenty-six out of 50 “PD-L1-positive” cases were EBVpositive and 3 out of 6 “PD-L1–negative” cases were EBVpositive. PD-L1 positivity did not show statistically significant
difference according to EBV expression (p = 1.00) (Table 3).
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3.4. PD-L1 expression and clinical parameters
Median patient age for PD-L1–positive cases was 25.5
years (7–80 years). PD-L1 was positive in 16 female and
34 male patients, and negative in 1 female and 5 male
patients. Two of the four stage-1 patients were “positive
for PD-L1”. PD-L1 was positive in all 19 stage-2 patients.
Seven of the 9 stage-3 patients were “positive for PD-L1.
Six of the 7 stage-4 patients were “positive for PD-L1”.
Six of 7 patients were positive for PD-L1 with splenic
involvement, though 28 of 32 were also PD-L1–positive
in uninvolved patients. Extranodal involvement was seen
in 4 patients, all positive for PD-L1. Three patients had
bone marrow involvement; all were positive for PD-L1.
Eighteen of 20 PD-L1–positive patients had B symptoms.
PD-L1 positivity did not show statistically significant
difference according to patient age (p = 0.131), sex (p =
1.000), disease stage (p = 1.000), splenic involvement (p
= 1.000), extralymphatic involvement (p = 1.000), bone

marrow involvement (p = 1.000), and B symptoms (p =
0.661) (Table 4).
3.5. PD-L1 expression and prognosis
Prognostic data from 34 patients was collected from
hospital records. 30 patients (88.2%) were “positive for
PD-L1”. Median overall survival (OS) of all 34 cases was 24
(4–108) months and median disease-free survival (DFS)
was 16 (0–96) months. For PD-L1–positive cases median
OS was 23 (4–108) months and median DFS was 14 (0–96)
months. For PD-L1–negative cases, median OS was 49 (8–
61) months and median DFS was 37 (2–57) months.
PD-L1 was positive in 23 (79.3%) of 27 patients
currently in remission. Recurrence was detected in 4 PDL1–positive patients during follow-up. However, 25 of 29
nonrecurrent patients were also positive for PD-L1. Two
PD-L1–positive patients died from the disease.
Prognostic factors did not show statistically significant
difference according to PD-L1 positivity (Table 5).

Table 1. Descriptive statistics.

Sex

Histological subtype

Stage

Splenic involvement
Extralymphatic involvement
Bone marrow involvement
B symptoms
EBV
Remission
Recurrence
Death from disease

1016

n

%

Female

17

30.4

Male

39

69.6

Nodular sclerosing

25

44.6

Mixed cellularity

29

51.8

Lymphocyte-rich

1

1.8

Lymphocyte-depleted

1

1.8

Stage 1

4

10.3

Stage 2

19

48.7

Stage 3

9

23.1

Stage 4

7

17.9

Positive

7

17.9

Negative

32

82.1

Positive

4

10.3

Negative

35

89.7

Positive

3

7.3

Negative

38

92.7

Positive

20

51.3

Negative

19

48.7

Positive

29

51.8

Negative

27

48.2

Positive

27

81.8

Negative

6

18.2

Positive

4

12.1

Negative

29

87.9

Positive

2

5.9

Negative

32

94.1
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Table 2. PD-L1 and EBV positivity rates according to histological subtypes.
PDL1

Histological
subtype

EBV

Negative

Positive

Negative

Positive

n

%

n

%

p

n

%

n

%

p

NSCHL

1

16.7

24

48.0

0.120

17

68

8

32

0.010

MCCHL

4

66.6

25

LRCHL

0

0.0

1

50.0

9

31

20

69

2.0

0

0.0

1

100

LDCHL

1

16.7

0

0.0

1

100

0

0.0

(NSCHL: Nodular sclerosing subtype, MCCHL: Mixed cellular type, LRCHL: Lymphocyte-rich subtype, LPCHL:
Lymphocyte-depleted subtype)

Table 3. Comparison of PD-L1 positivity according to EBV positivity.
PD-L1
Negative
EBV expression

Positive
n

%

n

%

p

Negative

3

50.0

24

48.0

1.000

Positive

3

50.0

26

52.0

Table 4. Comparison of PD-L1 positivity on HRS cells according to clinical data at the time of diagnosis.
PDL1
Negative
Median

Min–max

Median

56

7–80

25.5

n

%

n

Female

1

16.7

16

32.0

Male

5

83.3

34

68.0

Stage 1

2

40.0

2

5.9

Stage 2

0

0.0

19

55.9

Stage 3

2

40.0

7

20.6

Stage 4

1

20.0

6

17.6

Negative

4

80.0

28

82.4

Positive

1

20.0

6

17.6

Negative

5

100

30

88.2

Positive

0

0.0

4

11.8

Negative

5

100

33

91.7

Positive

0

0.0

3

8.3

Negative

3

60.0

16

47.1

Positive

2

40.0

18

52.9

Age (years)

Sex

Stage

Splenic involvement
Extralymphatic involvement
Bone marrow involvement
B symptoms

Positive
Min–max

p

3–85

0.131

%

p
0.655
1.000

1.000
1.000
1.000
0.661

1017

ÖZDEMİR et al. / Turk J Med Sci
Table 5. Comparison of prognosis in PD-L1–positive and PD-L1–negative cases.
PD-L1–negative

PD-L1–positive

Median

Min–max

Median

Min–max

p

Overall survival (month)

49

8–61

23

4–108

0.504

Disease-free survival (month)

37

2–57

14

0–96

0.538

n

%

n

%

p

Positive

4

100

23

79.3

1.000

Negative

0

0.0

6

20.7

Positive

0

0.0

4

13.8

Negative

4

100

25

86.2

Positive

0

0.0

2

6.7

Negative

4

100

28

93.3

Remission
Recurrence
Death

4. Discussion
Our study revealed a high rate (89.2%) of PD-L1 positivity
in HRS cells and all cases had tumour microenvironment
positive for PD-L1. EBV expression was statistically
significantly higher on mixed cellularity subtype. We did
not find a statistically significant difference between PDL1 positivity on HRS cells and EBV expression, clinical
parameters, and prognosis.
PD-L1 on the surface of antigen presenting cells
suppresses TCR production by stimulating PD1 on the
surface of T cells. This process causes anergy in T cells
[16,17]. In physiological conditions, it prevents tissue
damage and autoimmune reactions by prolonged and
excessive immune response via creating suppression in T
cells [18]. Tumours expressing PD-L1 protein acquire the
ability to escape cellular immunity by suppressing cytotoxic
T cells. Therefore, the PD1/PDL1 pathway has been the
target of newly emerging immunotherapy methods [19-21].
CHL is one of these tumours. PD-L1 expression has
been observed on both malignant HRS cells and cells
of tumour microenvironment [22,23]. Food and Drug
Administration (FDA) has approved nivolumab and
pembrolizumab, PD-1 inhibitors, in patients who do not
respond to routine chemotherapy with disease relapse
after bone marrow transplantation [8,9,19,24].
In our study, we found PD-L1 positivity in HRS cells
in 50 (89.2%) of 56 cases. Although different results were
obtained in various studies in the literature, increased
PD-L1 expression (20%–95.7%) was detected in HRS
cells in CHL. There are differences between the studies
related to various reasons, such as clone and evaluation
criteria and laboratory technique [10-15]. In our study,
E1L3N clone, which shows selective staining in HRS cells
and has been validated with standard clones, was used;
both staining intensity and prevalence were evaluated
[13,14,25-27].
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We found 89.2% PD-L1 positivity in CHL. It was like
those found by Chen et al. [10], Sakakibara et al. [12], Koh
et al. [13], Menter et al. [14], Inaguma et al. [15], DillyFeldis et al. [28], and Gerhard-Hartmann et al. [29], but
it was considerably higher than the result of Paydaş et al.
(20%) [11], Jimenez et al. (44%) [30], and Tanaka et al.
(62%) [31]. The results may differ due to PD-L1 clone and
evaluation criteria regarding staining quality and intensity.
Wei Xing et al. studied with E1L3N clone in bone
marrow of 44 CHL cases and diagnostic tissue biopsy
from 30 of them. They found 8 cases had bone marrow
involvement by CHL. All 8 of them had either 3+ or 2+
membranous staining for PD-L1. Moreover, all 30 of the
nonbone marrow diagnostic tissue had PD-L1 expression
in HRS and tumour microenvironment [32].
Fluorescence in situ hybridization (FISH) for PDL1 was used besides immunohistochemistry. Roemer
et al. found polysomia, copy number enhancement, or
amplification at the PD-L1 gene locus in 97% of their
cases, which was correlated with immunohistochemical
results [33]. Likewise, a study on patients of the German
Hodgkin Study Group NIVAHL trial showed copy
number alterations on PD-L1 locus in all specimens
with variable severity and 97% PD-L1 expression on
immunohistochemistry [29]. However, Jimenez et al.
found genetic alterations in only 38% of paediatric CHL
cases by FISH and 44% by immunohistochemistry [30].
However, FISH and immunohistochemistry results were
compatible in all these studies.
Sanger sequence method was used in one study on
40 paediatric CHL patients. Of the patients, 20.5% had
p.R260C and 7.7% had p.R234L mutations on exon 5
of PD-L1 locus [34]. In a small-scale next generation
sequencing (NGS) study performed on 4 CHL patients
who were positive for PD-L1 with immunohistochemistry,
despite 3 of the patients were PD-L1 amplified by FISH,
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none were amplified by NGS method [35]. Plasma levels of
PD-L1 in CHL cases were elevated but it was not correlated
with tissue expression by immunohistochemistry [36,37].
PD-L1 is expressed not only in neoplastic cells but also
by macrophages, lymphocytes, neutrophils, and fibroblasts
in the tumour microenvironment. Increased PD-L1
expression has been reported in background macrophages
in CHL cases [10-12]. Hollander et al. found significant
correlation between unfavourable prognosis and PD-L1
expression in the tumour microenvironment but they did
not find any correlation with PD-L1 expression on HRS
cells [38]. We observed PD-L1 positivity in macrophages
forming tumour microenvironment in all cases. Although
this makes it difficult to evaluate HRS, we observed HRS
cells staining more intense than the reactive cells in the
tumour background with E1L3N clone.
EBV positivity has been reported in approximately
20%–100% of CHL. Among the histological subtypes, it
was less common with nodular sclerosing subtype of CHL
than mixed cellularity subtype of CHL [5,6]. Studies have
shown that EBV can activate the PD-L1/PD-L2 gene locus
on 9p24.1 [39]. In our study, 29 (51.9%) of the cases were
found to have EBV positivity. It was significantly higher in
patients with mixed cellularity subtype of CHL than patients
with nodular sclerosing subtype of CHL (p = 0.010).
We compared PD-L1 positivity in EBV-positive
and -negative cases. PD-L1 positivity was similar in
both groups. Although there have been reports that the
presence of EBV correlates with PD-L1 expression [39],
we found no statistically significant relationship between
them. Other studies also support our results [12,13,15,40].
Publications that show correlation are mainly based on
the correlation between EBV positivity and aberrations or
promoter activation at the PD-L1 gene locus. However, no
such association was found in studies comparing EBV and
PD-L1 expression at protein level. This suggests that other
pathways leading to PD-L1 activation may also be present
in EBV-negative cases [41].
The effect of PD-L1 expression on clinical findings was
examined in various studies, and no correlation was found
[11,13,14]. However, in some studies, patients with 9p24.1
amplification showed advanced clinical stage and shorter
disease-free survival [33]. Sakakibara et al. performed
a study with SP142 clone, and they found lower PD-L1
positivity in lymphocyte-rich subtype of CHL cases [12].
Gül et al. found significant correlation between pR260c
mutation on exon 5 of PD-L1 gene and nodular sclerosing
subtype and event-free survival in older paediatric patients.
This may be due to decreased functionality in the mutant
protein [34]. In our study, clinical data of 39 patients were
examined, no significant relationship was found between
PD-L1 positivity and age, sex, histological subtype of CHL,
clinical stage, presence of spleen, bone marrow, or other

extranodal organ involvement at the time of diagnosis.
We reached follow-up records of 34 patients. We did not
find any difference between PD-L1–positive and -negative
cases in terms of total survival and disease-free survival. Total
follow-up period was 24 months (4–108 months). In the
study of Koh et al., there was no relationship between PD-L1
expression and overall survival in 109 patients. The median
follow-up period was 4.91 years (0.17–17.33 years) [13].
In our study, disease recurred in 4 cases, and 2 patients
died from disease. PDL1 was positive in all these cases.
However, this was not statistically significant. Paydaş
et al. found overall and disease-free survival in patients
expressing both PD1 and PD-L1 were significantly lower
[11]. Koh et al. reported that PD1-positive patients had
lower 5-year survival [13].
We found high rate of PD-L1 positivity in HRS cells,
and in APCs of the tumour microenvironment, but
without any correlation with EBV expression, clinical
findings, and prognosis. Despite the lack of clinical
correlation and PD-L1 expression of the tumour, the high
prevalence of PD-L1 positivity in HRS cells and APCs
gives hope for new therapeutic possibilities targeting the
programmed death pathway in these patients because
although modern therapeutic protocols have high success
rates, an important portion of the patients still cannot
achieve complete remission or relapses still occur.
Due to high PD-L1 expression rate, the positive and
negative groups were not evenly distributed. This caused
a bias when we compared positive and negative patients
for clinical parameters and prognosis. Another limitation
was that we could not reach the clinical data of all patients.
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